How to Trip Rapid Review
Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)
Step 2: press
Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.
- 1,294 results
- Evidence type
- Clinical Area
Use check boxes to select individual results below
SmartSearch available
Trip's SmartSearch engine has discovered connected searches & results. Click to show161. Partial seizures in children and young people with epilepsy: zonisamide as adjunctive therapy
). The most commonly reported adverse events were nasopharyngitis, weight loss and headache. Serious treatment-emergent adverse events were reported in 10 (6.9%) children and were considered to be treatment related in 3 cases (renal colic, foot fracture, and abdominal pain). Decreases in bicarbonate level of more than 3.5 mmol/L were observed in 64 (44.4%) children, but there were no reports of metabolic acidosis. These changes in bicarbonate levels were considered to be similar to those described (...) received placebo. The most common treatment-emergent adverse events in children aged 6–11 years were pyrexia (21.9%), headache (21.2%), upper respiratory tract infection (21.1%), decreased appetite (20.5%), rash (12.3%), somnolence (18.5%), vomiting (14.4%), fatigue (13.7%), nasopharyngitis (13.7%), sinusitis (11.0%), viral infection (11.0%), upper abdominal pain (10.3%), cough (10.3%), insomnia (10.3%) and nasal congestion (10.3%). In children and young people aged Partial seizures in children
2014 National Institute for Health and Clinical Excellence - Advice
162. Diagnosis and management of epilepsy in adults
count should not be monitored routinely. Diagnosis and management of epilepsy in adults 2 + 4 2 + 2+ 4 4 1 ++ 2 + 4| 19 4.6.4 BONE HEALTH Antiepileptic drug use is associated with a higher risk of clinical fracture, 145-149 with one systematic review reporting that AEDs increased the odds of fracture by 1.2 to 2.4 times. 148 The evidence is strongest for an association with phenobarbital, carbamazepine, clonazepam and sodium valproate. 148, 149 Bone mineral density is also lower in these patients (...) and many fractures are related to seizures. 148, 149 Postmenopausal women who use AEDs are at increased risk of fracture (hazard ratio (HR) 1.44, 95% CI 1.30 to 1.61) 145 and most AEDs were associated with an increased risk of non-traumatic factures in individuals aged 50 or over. 146 A systematic review found no RCTs investigating therapeutic agents to prevent fracture in people with epilepsy although one RCT included in the review suggested that supplementation with high dose vitamin D may
2015 SIGN
163. Cabometyx (cabozantinib) - advanced renal cell carcinoma
2016 European Medicines Agency - EPARs
166. Neofordex - dexamethasone. To treat adults with multiple myeloma
2016 European Medicines Agency - EPARs
167. Chronic Opioid Therapy for Chronic Non-Cancer Pain
of opioid prescription in incident opioid abuse and dependence among individuals with chronic noncancer pain: the role of opioid prescription. Clin J Pain. 2014;30:557-564. Food and Drug Administration. FDA Drug Safety Communication: FDA warns about serious risks and death when combining opioid pain or cough medicines with benzodiazepines; requires its strongest warning. Silver Spring, MD: U.S. Food and Drug Administration; August 31, 2016. Food and Drug Administration. FDA announces safety labeling (...) screening of the patient for potential comorbidities and risk factors using an appropriate screening tool. The screening should address: (i) History of addiction; (ii) Abuse or aberrant behavior regarding opioid use; (iii) Psychiatric conditions; (iv) Regular concomitant use of benzodiazepines, alcohol, or other central nervous system medications; (v) Poorly controlled depression or anxiety; (vi) Evidence or risk of significant adverse events, including falls or fractures; (vii) Receipt of opioids from
2016 Kaiser Permanente Clinical Guidelines
168. Point prevalence survey of healthcare-associated infections and antimicrobial use in European acute care hospitals ? protocol version 5.3
2016 European Centre for Disease Prevention and Control - Technical Guidance
169. National minimum retesting intervals in pathology: A final report detailing consensus recommendations for minimum retesting intervals for use in pathology
fracture or pain located in bone, suppression of other immune- globulin classes, renal impairment) and a band of 3 days for hCG) is a reliable indicator of residual tumour and a sig-nificant predictor of survival B- TM13 Serum ß-HCG (tumour marker) If rate of change in tumour marker concentration changes velocity, an urgent repeat to confirm the result is reasonable Sturgeon CM, Hoffman BR, Chan DW, Ch'ng SL, Hammond E, Hayes DF et al. National Academy of Clinical Biochemistry Laboratory Medicine
2016 Royal College of Pathologists
170. Nucala - mepolizumab
(OCS) or omalizumab (for the subgroup of patients with elevated IgE and who are allergic to a perennial allergen). Use of OCS on a regular basis has well-documented side effects. Short-term effects of OCS therapy include increased risk of glaucoma, fluid retention, increased blood pressure, mood swings, and weight gain. With long-term use of OCS, there is increased risk of cataracts, diabetes, infections, osteoporosis, fractures, menstrual irregularities, suppressed adrenal gland hormone production
2015 European Medicines Agency - EPARs
173. Duavive - oestrogens conjugated / bazedoxifene
of fracture. Duavive is indicated in postmenopausal women with a uterus (with 12 months since the last menses). When determining whether to use DUAVIVE or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see sections 4.4 and 5.1). The legal basis for this application refers to: Article 10(b) of Directive 2001/83/EC – relating to applications (...) postmenopausal symptoms in women with a uterus is progestin containing HRT which has been associated with vaginal bleeding, breast pain / tenderness, and increases in breast density. The combination of BZA with CE is considered by the Applicant to provide an alternative treatment option to progestin containing HRT. BZA has been approved in the EU as Conbriza ® and in Japan as Viviant ® for the treatment of postmenopausal osteoporosis in women at increased risk of fracture, and has also been approved
2015 European Medicines Agency - EPARs
174. Cerdelga - eliglustat
, discomfort, pain, and early satiety; fatigue; easy bruising/bleeding; splenic rupture; chronic bone pain and acute bone crises; osteonecrosis; marrow infarction; and pathological fractures. Three main clinical types of GD have been described, all of which are inherited in an autosomal recessive manner and caused by mutations in the GBA gene located at chromosome 1q22. The most common form, Gaucher disease type 1 (GD1), has historically been characterised as lacking central nervous system (CNS
2015 European Medicines Agency - EPARs
177. Vantobra - tobramycin
fibrosis (CF) is a hereditary, autosomal recessive chronic condition in which the chronic airway disease is a prominent complication present in more than 98% of patients. Its clinical features, which include chronic cough, are complemented by periodic episodes of exacerbations, characterised by increased sputum volume and purulence. Tobramycin, an aminoglycoside antibacterial agent, is the most frequently used antibiotic for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa
2015 European Medicines Agency - EPARs
To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>